Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 21Lymphoma 18Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Multiple Myeloma 11Burkitt Lymphoma 11Leukemia 10Lymphoma, Mantle-Cell 9Myelodysplastic Syndromes 8Melanoma 8Lymphoma, B-Cell, Marginal Zone 7Triple Negative Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Chronic-Phase 4

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mesothelin-positive Advanced Refractory Solid Tumors × Cyclophosphamide × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡